This is not the most recent version of the article. View current version (20 JAN 2010)

Intervention Review

You have free access to this content

Treatment of latent tuberculosis infection in HIV infected persons

  1. Jimmy Volmink2,
  2. Sara Woldehanna1,*

Editorial Group: Cochrane HIV/AIDS Group

Published Online: 7 OCT 2009

Assessed as up-to-date: 25 NOV 2003

DOI: 10.1002/14651858.CD000171.pub2

Database Title

Additional Information

How to Cite

Volmink J, Woldehanna S. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database of Systematic Reviews 2004, Issue 1. Art. No.: CD000171. DOI: 10.1002/14651858.CD000171.pub2.

Author Information

  1. 1

    Academy for Educational Development, Center for Health Communication , Washington, DC, USA

  2. 2

    University of Stellenbosch, Faculty of Health Sciences, Tygerberg, South Africa

*Sara Woldehanna, Center for Health Communication , Academy for Educational Development, 1825 Connecticut Avenue NW, Washington, DC, 20009-5721, USA. swoldehanna@aed.org.

Publication History

  1. Publication Status: Unchanged
  2. Published Online: 7 OCT 2009

SEARCH

ARTICLE TOOLS

This is not the most recent version of the article.View current version (20 Jan 2010)

View Full Article (HTML) Summary (59K)Standard (290K)Full (569K)
[Analysis 1.1]
Analysis 1.1. Comparison 1 Any TB drug vs placebo, Outcome 1 Incidence of active TB (confirmed, probable or possible).
[Analysis 1.2]
Analysis 1.2. Comparison 1 Any TB drug vs placebo, Outcome 2 Incidence of confirmed TB.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Any TB drug vs placebo, Outcome 3 Incidence of death (all cause).
[Analysis 1.4]
Analysis 1.4. Comparison 1 Any TB drug vs placebo, Outcome 4 Incidence of AIDS.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Any TB drug vs placebo, Outcome 5 Incidence of adverse events leading to stopping treatment.
[Analysis 1.10]
Analysis 1.10. Comparison 1 Any TB drug vs placebo, Outcome 10 Mean time to AIDS.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Isoniazid vs placebo, Outcome 1 Incidence of active TB (confirmed, probable or possible).
[Analysis 2.2]
Analysis 2.2. Comparison 2 Isoniazid vs placebo, Outcome 2 Incidence of confirmed TB.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Isoniazid vs placebo, Outcome 3 Incidence of death (all cause).
[Analysis 2.4]
Analysis 2.4. Comparison 2 Isoniazid vs placebo, Outcome 4 Incidence of AIDS.
[Analysis 2.5]
Analysis 2.5. Comparison 2 Isoniazid vs placebo, Outcome 5 Incidence of adverse events leading to stopping treatment.
[Analysis 2.10]
Analysis 2.10. Comparison 2 Isoniazid vs placebo, Outcome 10 Mean time to AIDS.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Isoniazid + rifampicin vs placebo, Outcome 1 Incidence of active TB (confirmed, probable or possible).
[Analysis 3.2]
Analysis 3.2. Comparison 3 Isoniazid + rifampicin vs placebo, Outcome 2 Incidence of confirmed TB.
[Analysis 3.3]
Analysis 3.3. Comparison 3 Isoniazid + rifampicin vs placebo, Outcome 3 Incidence of death (all cause).
[Analysis 3.5]
Analysis 3.5. Comparison 3 Isoniazid + rifampicin vs placebo, Outcome 5 Incidence of adverse events leading to stopping treatment.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Rifampicin + pyrazinimide vs placebo, Outcome 1 Incidence of active TB (confirmed, probable or possible).
[Analysis 4.2]
Analysis 4.2. Comparison 4 Rifampicin + pyrazinimide vs placebo, Outcome 2 Incidence of confirmed TB.
[Analysis 4.3]
Analysis 4.3. Comparison 4 Rifampicin + pyrazinimide vs placebo, Outcome 3 Incidence of death (all cause).
[Analysis 4.5]
Analysis 4.5. Comparison 4 Rifampicin + pyrazinimide vs placebo, Outcome 5 Incidence of adverse events leading to stopping treatment.
[Analysis 5.1]
Analysis 5.1. Comparison 5 Isoniazid + rifampicin + pyrazinamid vs placebo, Outcome 1 Incidence of active TB (confirmed, probable or possible).
[Analysis 5.3]
Analysis 5.3. Comparison 5 Isoniazid + rifampicin + pyrazinamid vs placebo, Outcome 3 Incidence of death (all cause).
[Analysis 5.5]
Analysis 5.5. Comparison 5 Isoniazid + rifampicin + pyrazinamid vs placebo, Outcome 5 Incidence of adverse events leading to stopping treatment.
[Analysis 6.1]
Analysis 6.1. Comparison 6 Isoniazid vs rifampicin + pyrazinimide, Outcome 1 Incidence of active TB (confirmed, probable or possible).
[Analysis 6.2]
Analysis 6.2. Comparison 6 Isoniazid vs rifampicin + pyrazinimide, Outcome 2 Incidence of confirmed TB.
[Analysis 6.3]
Analysis 6.3. Comparison 6 Isoniazid vs rifampicin + pyrazinimide, Outcome 3 Incidence of death (all cause).
[Analysis 6.5]
Analysis 6.5. Comparison 6 Isoniazid vs rifampicin + pyrazinimide, Outcome 5 Incidence of adverse events leading to stopping treatment.
[Analysis 7.1]
Analysis 7.1. Comparison 7 Isoniazid vs isoniazid + rifampicin, Outcome 1 Incidence of active TB (confirmed, probable or possible).
[Analysis 7.2]
Analysis 7.2. Comparison 7 Isoniazid vs isoniazid + rifampicin, Outcome 2 Incidence of confirmed TB.
[Analysis 7.3]
Analysis 7.3. Comparison 7 Isoniazid vs isoniazid + rifampicin, Outcome 3 Incidence of death (all cause).
[Analysis 7.5]
Analysis 7.5. Comparison 7 Isoniazid vs isoniazid + rifampicin, Outcome 5 Incidence of adverse events leading to stopping treatment.
[Analysis 8.1]
Analysis 8.1. Comparison 8 Isoniazid + rifampicine vs Rifampicin + Pyrazinimide, Outcome 1 Incidence of active TB (confirmed, probable or possible).
[Analysis 8.2]
Analysis 8.2. Comparison 8 Isoniazid + rifampicine vs Rifampicin + Pyrazinimide, Outcome 2 Incidence of confirmed TB.
[Analysis 8.3]
Analysis 8.3. Comparison 8 Isoniazid + rifampicine vs Rifampicin + Pyrazinimide, Outcome 3 Incidence of death (all cause).
[Analysis 8.5]
Analysis 8.5. Comparison 8 Isoniazid + rifampicine vs Rifampicin + Pyrazinimide, Outcome 5 Incidence of adverse events leading to stopping treatment.
[Analysis 9.1]
Analysis 9.1. Comparison 9 Isoniazid vs isoniazid + rifampicin + Pyrazinamide, Outcome 1 Incidence of active TB (confirmed, probable or possible).
[Analysis 9.3]
Analysis 9.3. Comparison 9 Isoniazid vs isoniazid + rifampicin + Pyrazinamide, Outcome 3 Incidence of death (all cause).
[Analysis 9.5]
Analysis 9.5. Comparison 9 Isoniazid vs isoniazid + rifampicin + Pyrazinamide, Outcome 5 Incidence of adverse events leading to stopping treatment.
[Analysis 10.1]
Analysis 10.1. Comparison 10 Isoniazid + rifampicin vs isoniazid + rifampicin + Pyrazinamide, Outcome 1 Incidence of active TB (confirmed, probable or possible).
[Analysis 10.3]
Analysis 10.3. Comparison 10 Isoniazid + rifampicin vs isoniazid + rifampicin + Pyrazinamide, Outcome 3 Incidence of death (all cause).
[Analysis 10.5]
Analysis 10.5. Comparison 10 Isoniazid + rifampicin vs isoniazid + rifampicin + Pyrazinamide, Outcome 5 Incidence of adverse events leading to stopping treatment.
[Analysis 22.2]
Analysis 22.2. Comparison 22 Isoniazid vs placebo (stratified by AIDS status at baseline), Outcome 2 Incidence of confirmed TB.
[Analysis 22.3]
Analysis 22.3. Comparison 22 Isoniazid vs placebo (stratified by AIDS status at baseline), Outcome 3 Incidence of death (all cause).
[Analysis 26.2]
Analysis 26.2. Comparison 26 Isoniazid vs rifampicin + pyrazinimide (stratified by AIDS status at baseline), Outcome 2 Incidence of confirmed TB.
[Analysis 26.3]
Analysis 26.3. Comparison 26 Isoniazid vs rifampicin + pyrazinimide (stratified by AIDS status at baseline), Outcome 3 Incidence of death (all cause).
View Full Article (HTML) Summary (59K)Standard (290K)Full (569K)